港股異動丨信達生物(1801.HK)午後漲幅一度擴大超10% 將於本月30日放榜
格隆匯3月25日丨信達生物-B(1801.HK)午後漲幅進一度擴大超10%,現漲8.87%,報31.3港元,暫成交7942萬港元,最新總市值420.18億港元。信達生物於3月30日舉行董事會會議 以審批年度業績。3月以來累獲摩通與瑞銀看好。摩通升信達生物目標價至38港元,予“增持”評級。瑞銀則表示,公司管理層指出公司運營正常,其股價過去兩週持續下跌,股價營收比相對行業較低,認為尚未反映其行業龍頭的利好因素,目標價由32.2港元升至37.73港元,維持其“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.